Introduction
Phosphoinositide 3-kinase (PI3-kinase) is a lipid kinase that transfers ATP to the D3 position of phosphoinositides (PtdIns), followed by production of PtdIns-3-P, PtdIns-3,4-P 2 , and PtdIns-3,4,5-P 3 (Fruman et al., 1998; Stein and Waterfield, 2000; Wymann and Pirola, 1998) . Among these second messengers, PtdIns-3,4,5-P 3 demonstrates the most potent activity for downstream signal transduction pathways. PtdIns-3,4,5-P 3 activates phosphoinositide-dependent kinase-1, which in turn activates a panel of serine/threonine kinases, such as p70 S6 kinase ( p70 s6k ) and c-Akt/protein kinase B (PKB) (Chan et al., 1999; Duronio et al., 1998; Toker and Newton, 2000) . PI3-kinase is involved in many cellular responses including proliferation, migration, and survival of normal and tumor cells (Fruman et al., 1998; Stein and Waterfield, 2000; Wymann and Pirola, 1998) . It is also proposed that this kinase is involved in the tumor progression and angiogenesis in vivo (Jiang et al., 2000; Stein and Waterfield, 2000; Roymans and Slegers, 2001 ). Thus, inhibition of this enzyme is proposed to be one of the important strategies for the control of malignancies.
Regulation of PI3-kinase activity is rather complex (Fruman et al., 1998; Wymann and Pirola, 1998) . Class I PI3-kinase is composed of p85 regulatory subunit and p110 catalytic subunit. p85 regulatory subunit has an Src homology (SH) 3 domain followed by the 2 SH2 domains split by interSH2 domain. InterSH2 domain constitutively associates with p110 catalytic subunit. Tyrosine phosphorylated YXXM motif is the target of the binding site for the SH2 domain of p85 subunit (Songyang et al., 1993) . Cytoplasmic region of plateletderived growth factor (PDGF) receptor and insulin receptor substrate-1 have this motif (Ogawa et al., 1998; Wennstrom et al., 1992) . Direct association of p85 subunit with phosphotyrosine-containing proteins close to plasma membrane subsequently recruits p110 catalytic subunit to the plasma membrane, resulting the increase in kinase activity (Holt et al., 1994; Klippel et al., 1992 Klippel et al., , 1996 . Another mechanism of activation of PI3-kinase is the direct binding of p110 catalytic subunit to GTP-loaded Ras (Rodriguez-Viciana et al., 1994a,b) .
Fibroblast growth factor (FGF) activates its specific receptor tyrosine kinases, FGFR1 -4 (Boilly et al., 2000; Klint and Claesson-Welsh, 1999) . FGF induces an extremely weak activation of PI3-kinase (Kanda et al., 1997; van Weering et al., 1998) , compared to other receptor tyrosine kinases. No increase in PI3-kinase activity was observed in anti-phosphotyrosine immu-noprecipitates of FGF-2-treated cells (Kanda et al., 1997; van Weering et al., 1998) , and transient expression of dominant negative Ras completely abolished the PI3-kinase activation.
Plasminogen activator (PA) is a key enzyme involved in digestion of basement membrane components to allow cells to invade into surrounding tissues. This step is involved in both tumor invasion and the initial step of angiogenesis (see reviews; Aguirre-Ghiso et al., 1999a; Blasi, 1993) . This protease itself has serine protease activity and also acts as an upstream regulator of plasmin and matrix metalloproteases (MMPs). PA, plasmin, and MMPs cooperatively digest surrounding extracellular matrix proteins. PA is classified into two types, urokinase-type (uPA) and tissue-type (tPA), respectively. Since tPA is usually secreted, uPA frequently exists as a cell-associated form with its cell surface receptor. Although mitogen-activated protein kinase (MAPK) is an only signaling molecule identified in FGF-2-mediated uPA production (Giuliani et al., 1999) , other pathways have never been studied in this process.
We have previously established a murine brain capillary endothelial cell line, denoted IBE cells (Kanda et al., 1996) . To elucidate the molecular mechanisms underlying FGF-2-mediated uPA secretion by IBE cells, the effects of pharmacological inhibitors on uPA secretion were examined and it was found that PI3-kinase inhibitor upregulated uPA production in FGF-2-treated IBE cells. In addition, similar results were obtained from PAE cells and L6 myoblasts ectopically expressing FGFR1. Stable expression of membrane-targeted, activated form of p110a catalytic subunit attenuated FGF-2-induced uPA production in IBE cells. We also examined the manner to activate PI3-kinase by FGF-2 and found that FGF-2-mediated PI3-K activation was activated Ras-dependent. Considered collectively, these data suggest that PI3-kinase activation by FGF-2 is dependent on activated Ras and its activity is involved in downregulation of uPA production in FGF-2-treated cells.
Results

FGF-2-mediated uPA induction was upregulated by PI3-kinase inhibitors
An important early event in angiogenesis is the degradation of proteins in the basement membrane of blood vessels to allow endothelial cells to invade into the surrounding interstitial tissue (Pepper et al., 1996) . uPA has been implicated in this process. However, molecular mechanisms underlying FGF-mediated uPA regulation are largely unknown. We first screened the effect of pharmacological inhibitors on FGF-2-induced uPA secretion by IBE cells. FGF-2 potently stimulated uPA production by IBE cells and the amount of secreted form of uPA in the culture medium was much higher than cell-associated form (Kanda et al., 1996) . We then examined the uPA activity in culture supernatant of IBE cells. MEK inhibitor PD98059 dosedependently inhibited both basal and FGF-2-mediated uPA secretion (Figure 1a) , which was consistent with the previous report (Giuliani et al., 1999) . Conversely, PI3-kinase inhibitors, LY294002 and wortmannin, upregulated both basal and FGF-2-mediated uPA secretion ( Figure 1a) . Secretion of plasminogen activator inhibitor 1 (PAI 1)-associated uPA was under detectable level. A protein kinase C inhibitor bisindolylmaleimide and a Src family kinase inhibitor PP2 had no remarkable effect on uPA secretion by IBE cells (data not shown). We next examined the effect of LY294002 on PAE cells and L6 myoblast expressing human FGFR1 (Klint et al., 1995) . In these cells, PA activity was largely associated with cell surface, and was a urokinase type as have been judged by the amiloride-sensitivity (Vassalli and Belin, 1987 ; data not shown). Figure 1b shows that uPA production by PAE cells was increased when FGF-2 was present in both free and PAI-1-associated forms. LY294002 upregulated FGF-2-induced uPA production, but not basal Figure 1 (a) PI3-kinase inhibitors, wortmannin and LY294002, upregulate FGF-2-mediated uPA secretion by IBE cells, whereas MEK inhibitor PD98059 shows opposite effect. Conditioned medium from equal numbers of IBE cells with indicated treatments were electrophoresed on SDS-polyacrylamide gels and after the removal of SDS, gels were overlaid horizontally onto caseinand plasminogen-containing agarose gels. The concentration of FGF-2 in these experiments was 5 ng/ml. Maximum uPA secretion was noted at this concentration. Caseinolysis was observed as a lucent band, which was visualized on a black paper. The intensity of each band was quantitated by NIH Image version 1.52 and the ratio of the densities of indicated proteins in lanes of untreated cells was set as 1.00. FGF-2-mediated uPA production by PAE cells (b) and FGFR1-expressing L6 myoblasts (c) is upregulated by LY294002-treatment. Cell extracts from indicated treatment were prepared and equal amounts of proteins were separated onto SDS-polyacrylamide gels and uPA activity was measured. Reproducible data were obtained from three to five independent experiments. LY; LY294002, Wort; wortmannin, PD; PD98059 Regulation of uPA production by PI3-kinase Y Mochizuki et al uPA activity in PAE cells. As shown in Figure 1c , basal uPA activity was affected by LY294002 in FGFR1-expressing L6 myoblasts. However, FGF-2-mediated uPA production was increased by the inhibitor. These data suggest that FGF-2-induced upregulation of uPA production was downregulated by PI3-kinase activity and the effect of LY294002 on the basal level of uPA was dependent on the cell types.
Expression of myristylated form p110a catalytic subunit negatively regulates uPA production in FGF-2-treated IBE cells
We next transfected C-terminally Myc-tagged, Nterminally myristylated bovine p110a catalytic subunit (Myr.p110), which exhibits constitutive activation, into IBE cells. Stable expression was screened by the in vitro PI3-kinase assay. Two stable cell lines, denoted Myr.p110-8 and -12 cells, respectively, were obtained. As shown in Figure 2 , increase in PI3-kinase activity in proteins immunoprecipitated with anti-Myc antibody was observed in these cells. We examined FGF-2-mediated uPA induction by these cells. FGF-2 induced uPA secretion dose-dependently by parental cells (Figure 3 ). In contrast, FGF-2 at 1 ng/ml showed no increase in uPA activity and at 5 ng/ml, uPA secretion was weakly stimulated in Myr.p110 cells (Figure 3 ). These results indicate that increased basal activity of PI3-kinase negatively regulated FGF-2-mediated uPA secretion.
FGF-2-mediated PI3-kinase activation depends on activated Ras
We next focused on the molecular mechanism underlying FGF-2-mediated PI3-kinase activation. Activation of PI3-kinase is rather complicated and is regulated by several mechanisms. However, two major pathways are well known downstream of growth factor receptor tyrosine kinases. One pathway is that the phosphorylated tyrosine residue followed by the classical consensus motif (YXXM) of the intracellular domain of receptor tyrosine kinase or receptorassociated adapter proteins bind to SH2 domain of p85 regulatory subunit. Subsequently, p110 catalytic subunit is recruited to the plasma membrane and the association of p85 with phosphotyrosine-containing peptides itself further enhances catalytic activity. Under this mechanism, strong activation of PI3-kinase occurs and increase in its activity is observed in immunoprecipitates with anti-phosphotyrosine antibody (van Weering et al., 1998) . The second mechanism is that p110 catalytic subunit directly binds to GTP-loaded Ras, which in turn activates catalytic activity of p110 subunit. It has been reported that Y730 is one of the autophosphorylation sites of FGFR1 and is followed by the consensus motif for p85 . To investigate the activation of PI3-kinase by FGF-2 in detail, we examined FGF-2 mediated PI3-kinase activity in immune complex with different types of antibodies. PI3-kinase activity did not increase in anti-phosphotyrosine immunoprecipitates when stimulated with 100 ng/ml FGF-2, but increased by EGFtreatment (Figure 4a ). On the other hand, FGF-2 stimulated PI3-kinase activity was increased in either anti-p85 antibody or anti-p110 antibody immunoprecipitates (Figure 4b,c) , suggesting that FGF-2 mediated PI3-kinase activation did not depend on the association of p85 subunit with tyrosine phosphorylated proteins. We then transfected IBE cells with deleted mutant of p85 subunit, which can not associate with p110 catalytic subunit and demonstrated dominant negative effect on insulin-mediated PI3-kinase activation (Kotani et al., 1994) . Two stable cell lines were obtained, denoted, Dp85-8 and -12 cells, respectively, which represented dominant negative effect on EGF-stimu- Figure 2 Establishment of IBE cell lines expressing activating mutant p110a catalytic subunit of bovine PI3-kinase. Expression phagemid containing cDNA encoding N-terminally myristylated and C-terminally Myc-tagged bovine p110a catalytic subunit was transfected into IBE cells and after screening of G418-resistant clones, cell lysate from each clone was immunoprecipitated with anti-Myc antibody followed by immunocomplex PI3-kinase assay. Phosphatidylinositol was separated by thin layer chromatography and phosphorylation of phosphatidylinositol was measured by the BioImager BAS 5000. The activity of phosphatidylinositol 3-phosphate (PIP) in untransfected cells was set as 1.00. Reproducible data were obtained from three to four independent experiments Figure 3 Expression of myristylated bovine p110a catalytic subunit into IBE cells decreases FGF-2-mediated uPA secretion. Cells were prepared, cultured in the presence or absence of indicated concentrations of FGF-2 for 24 h, then culture supernatant was collected. uPA activity in the supernatant was examined as described in the legend of Figure 1 . Reproducible data were obtained from three to four independent experiments Regulation of uPA production by PI3-kinase Y Mochizuki et al lated PI3-kinase activation (Figure 5a ). Using these cells, PI3-kinase activation by FGF-2 was examined in immunoprecipitates of anti-p110 antibody. As shown in Figure 5b , stable expression of mutant p85 exhibited no dominant negative effect on FGF-2-mediated PI3-kinase activation. In addition, FGF-2-stimulated uPA secretion by Dp85 cells was increased in a dosedependent manner, which was similar to that by parental cells (Figure 6 ). Finally, dominant negative Ras (S17N) was transiently expressed in IBE cells and FGF-2-mediated PI3-kinase activation was examined. Figure 7 shows that activation of PI3-kinase by FGF-2 was abolished. These results suggest that FGF-2-mediated PI3-kinase activation was Ras-dependent in IBE cells.
Discussion
In the present study, we reported for the first time that PI3-kinase was a negative regulator for FGF-2-mediated uPA production. Previous reports demonstrated that PI3-kinase activation by FGF-2 seemed to depend on the activated Ras (van Weering et al., 1998). Our results are consistent with their previous data, since the expression of deleted mutant p85 subunit, which could not associate with p110, had no effect and no increase in PI3-kinase activity in immunoprecipitates with ant-phosphotyrosine antibody was observed in FGF-2-treated cells. Recently, tyrosine phosphorylation and association of adaptor protein Gab 1 with Figure 4 Phosphotyrosine-independent activation of PI3-kinase in FGF-2-treated IBE cells. IBE cells were serum-starved overnight. Cells were either stimulated or left unstimulated with 100 ng/ml of either EGF or FGF-2 for 5 min and then washed, lysed, and PI3-K activity was immunoprecipitated with indicated antibodies (a) anti-phosphotyrosine antibodies, (b) anti-p85a antibody, (c) anti-p110a antibody. Reproducible data were obtained from four to five independent experiments Figure 5 FGF-2-mediated activation of PI3-kinase was p85a regulatory subunit-independent. (a) Expression of deletion mutant p85a, that has 32 amino acids deletion in inter-SH2 domain, led to inability of association with p110a catalytic subunit in IBE cells. D-p85-8 and D-p85-12 cells demonstrated dominant negative effect on EGF-mediated PI3-kinase activation in anti-phosphotyrosine-immunoprecipitates. Representative data were obtained from two independent experiments. (b) FGF-2 mediates PI3-kinase activation independent of the expression of deletion mutant p85a in IBE cells. Either parental, D-p85-8, or D-p85-12 cells were stimulated or left unstimulated by FGF-2 and immune complex kinase assay in p110a immunoprecipitates was performed. Reproducible data were obtained from three independent experiments Figure 6 Expression of deleted mutant p85a subunit in IBE cells has no effect on FGF-2-mediated uPA secretion. Cells were prepared and culture supernatant was collected, followed by examination of uPA activity as described in the legend of Figure 1 . Reproducible data were obtained from three independent experiments Figure 7 Transient expression of dominant negative H-Ras (S17N) downregulates FGF-2-mediated PI3-kinase activation. Expression plasmid encoding dominant negative H-Ras or empty vector was transfected and 66 h later, cells were either stimulated or left unstimulated with 100 ng/ml FGF-2 for 5 min. Cells were lysed and PI3-kinase activity was examined in the immunoprecipitated proteins by anti-p85a antibody. Reproducible data were obtained from five independent experiments PI3-kinase was reported (Ong et al., 2001) . However, increase in PI3-kinase activity in anti-phosphotyrosine immunoprecipitates was only shown in FGF-1-treated PC12 cells (Ong et al., 2001; Raffioni and Bradshow, 1992) , suggesting that FGF-mediated increase in PI3-kinase activity associated with phosphotyrosine containing proteins may depend on the cell types.
uPA plays a central role in the regulation of proteolysis. Regulation of uPA production is largely dependent on MAPK activation and MAPK is activated via many growth factor receptors and cytokine receptors including FGFR1 (Aguirre-Ghiso et al., 1999a). Recently, PLD activation through the activation of RalA (Aguirre-Ghiso et al., 1999b), RelA (Wang et al., 1999) , and Rac/Jun NH 2 -terminal kinase pathway (Gum et al., 1998) has been shown to be involved in upregulation of uPA. However, the role of PI3-kinase on the regulation of uPA production has never been reported. Recently, the relationship between PI3-kinase pathway and MAPK pathway was reported. PKB/c-Akt down-regulated Raf-1 kinase activity, which in turn, down-regulated MAPK activation (Rommel et al., 1999; Zimmermann and Moelling, 1999) . Conversely, inhibition of PI3-kinase by inhibitors or the expression of dominant negative protein resulted in a decrease in MAPK activity (Sutor et al., 1999; Wennstrom and Downward, 1999) . These controversial reports may depend on the used cell types. However, the former case did not match the present study, because FGF-2-mediated MAPK activation was not affected by PI3-kinase inhibitors in IBE cells (data not shown). It is therefore possible that upregulation of uPA secretion by the inhibition of PI3-kinase was not due to the upregulation of MAPK by suppressing PKB/c-Akt.
In FGF-2-stimulated cells, inhibition of PI3-kinase is linked to upregulation of uPA. The effect was rather specific for FGF-2-mediated signaling. IBE cells treated with EGF secreted uPA to a lesser extent (Kanda et al., 1996) . Treatment of EGF-stimulated cells with PI3-kinase inhibitors attenuated uPA secretion and similar results were obtained in hepatocyte growth factor (HGF)-mediated uPA production in human renal carcinoma cells (S Kanda, unpublished observation). FGF-2-mediated PI3-kinase activation is weaker than that by EGF and HGF. In addition, in cells treated by EGF and HGF, PI3-kinase activity associated with proteins containing phosphotyrosine. The degree of activation and/or association of p85 with phosphotyrosine residues may affect the distinct signaling pathways leading to the regulation of uPA production. However, some tumor cells depend to proliferate and migrate on FGFs and FGF-dependent angiogenesis do exist. In addition, the balance of the amount between uPA and PAI-1 is important for tumor progression and angiogenesis (Bajou et al., 1998 (Bajou et al., , 2001 ). Thus, application of PI3-kinase inhibitors for cancer therapy should be carefully determined.
In the present study, downstream signaling molecules of PI3-kinase were not identified. Treatment of cells with rapamycin, an inhibitor of TOR that activates p70 s6k , had no effect on FGF-2-induced uPA production (data not shown). Recently, E2F1 transcription factor repressed uPA gene expression independent of pocket proteins, such as pRB, p107, and p130 (Koziczak et al., 2000) . Activation of PI3-kinase via FGFR may utilize this pathway to downregulate uPA production.
Materials and methods
Antibodies
Anti-phosphotyrosine monoclonal antibody (PY99) was obtained from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA). Anti-phosphotyrosine monoclonal antibody (PY20) was from Transduction Laboratories Inc. (Lexington, KT, USA). Anti-p85a polyclonal antibody, anti-p110a polyclonal antibody, and anti-Myc monoclonal antibody (9E10) were from Upstate Biotechnologies, Inc. (Lake Placid, NY, USA).
Cell culture
Murine brain capillary endothelial cells, denoted IBE cells, were isolated from H-2K
b -tsA58 transgenic mice and grown routinely as described previously (Kanda et al., 1996) . Experiments using IBE cells were carried out at 338C. L6 myoblasts expressing human wild-type FGFR1 (L6/FR1), and PAE cells were kind gifts from Dr Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden. Experiments using these cells were performed at 378C.
Inhibitors of signal transduction pathway
PD98059 as obtained from New England Biolabs, Inc. (Beverly, MA, USA). Wortmannin and LY294002 were purchased from Calbiochem-Novabiochem (La Jolla, CA, USA). All chemicals were dissolved in dimethyl sulfoxide (DMSO) as stock solutions and stored at 7308C until use. Stock solutions were diluted with DMSO and dissolved in culture medium, then added to the cells at indicated concentrations. Final concentration of DMSO was 0.1% in all cases. Thirty minutes later, cells were either treated or left untreated with FGF-2 for the indicated periods.
Transfection of activated mutant and deletion mutant of PI3-kinase constructs into IBE cells pGEX plasmid encoding cDNA of deleted mutant p85a regulatory subunit of bovine PI3-kinase, which does not interact with p110 subunit (Kotani et al., 1994) and pBluescript plasmid encoding C-terminally Myc-tagged, myristylated p110a catalytic subunit of bovine PI3-kinase (Kotani et al., 1999) were kind gifts from Drs Wataru Ogawa and Masato Kasuga (Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan). Both constructs were subcloned into pBK -CMV phagemid (Stratagene, La Jolla, CA, USA) and either empty pBK -CMV or expression phagemid containing either constructs were transfected into IBE cells by the use of TFL-5 liposomes, which were kind gifts from Dr Hiroshi Kikuchi (Daiichi Pharmaceuticals, Tokyo, Japan). Twelve G418-resistant clones from each transfection were picked up and examined for the dominant negative effect or increased activities by in vitro PI3-kinase assay as described below.
Regulation of uPA production by PI3-kinase Y Mochizuki et al Transient transfection of dominant negative mutant of H-Ras pUSE expression vector encoding dominant negative Ha-Ras (S17N), which was obtained from Upstate Biotechnology, was transiently transfected into IBE cells with TFL liposomes. Sixty-six hours later, cells were lysed and clarified lysate was immunoprecipitated with anti-p85 antibody for in vitro PI3-kinase assay.
Zymographic assay for determination of plasminogen activator activity
Zymographic assay for the determination of PA activity was described previously (Kanda et al., 1996) . IBE cells were inoculated in fibronectin-and gelatin-coated 24-well plates and after serum-free culture for 24 h, cells in fresh Ham's F-12 medium containing 0.25% BSA was either treated or left untreated with inhibitors of signal transduction pathway at indicated concentrations. After 30 min, FGF-2 was added to indicated cells at indicated concentrations and the culture was continued for 24 h. The culture supernatant was collected and aliquots of supernatants were electrophoresed in SDSpolyacrylamide gels (10% polyacrylamide) under non-reducing conditions. Gels were washed extensively to remove SDS and placed horizontally on top of 1.2% agarose gel containing 1.2% non-fat dry milk (as a source of casein) and 0.12 units/ml plasminogen (Carbiochem-Novabiochem), then incubated at 378C until the appearance of the lucent PA band. PA activity was visualized as a translucent area in the white gel. Photographs of gels were taken on a black paper and the intensity of each band was calculated by NIH Image version 1.52 and the ratio of the densities of indicated proteins in lanes of untreated cells was set as 1.00. For the examination of L6 and PAE cells, they were plated in 24-well plates at 5610 4 cells/well. After 24 h, cells were washed twice with Ham's F-12 medium and incubated in fresh medium containing 0.5% FBS for 12 h at 378C (Roghani et al., 1996) . The medium was replaced with fresh medium containing 0.5% FBS with or without the inhibitor of signal transduction pathway at indicated concentration. After 30 min, 5 ng/ ml FGF was added if necessary. After incubation for 12 h, cells were washed once with Ham's F-12 and lysed with 0.5% Triton X-100 in 0.1 M Tris-HCl, pH 8.0. The protein concentration in each lysate was determined by the DC protein assay reagent (Bio-Rad Laboratories, Hercules, CA, USA). An equal amount of proteins from each lysate was electrophoresed in SDS-polyacrylamide gels, followed by the method described above.
In vitro PI3-kinase assay
In vitro kinase assay for PI3-kinase was performed as described previously (Kanda et al., 1997) . In brief, IBE cells were serum-starved with Ham's F-12 medium supplemented with 0.25% bovine serum albumin (BSA) and cultured overnight at 338C. Cells were then either stimulated or left unstimulated with 100 ng/ml of the indicated growth factors for 5 min, then rinsed and lysed in Nonidet P-40 (NP-40) lysis buffer. Clarified cell lysates were immunoprecipitated with indicated antibodies, followed by absorption with Protain A-agarose beads. Beads were extensively washed, suspended in 47.5 ml of 25 mM HEPES, pH 7.5, containing 100 mM NaCl, 0.5 mM ethylene glycol bis-(b-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), and 10 mg of phosphatidylinositol (Sigma Chemical Co., St. Louis, MO, USA), then incubated for 10 min at room temperature. MgCl 2 at 10 mM and 0.37 MBq/sample of [g-32 P]ATP were added and samples were further incubated for 10 min at room temperature. The reaction was stopped and reaction products were extracted with chloroform, then concentrated in vacuo, followed by the separation of thin layer chromatography on silica Gel-60 plates (Merck). Phosphorylated products were detected and incorporation of [g-32 P]ATP was measured by Image Analyzer BAS 5000 (Fuji), followed by exposure on X-ray films (Amersham-Pharmacia BioTech).
